Enhanced Targeted Drug Delivery System to Control Avidity and Drug Encapsulation Using E2 Nanocages and SpyTag/SpyCatcher
ACS Biomaterials Science & Engineering · 12.05.2025 · 11 (5) · 2768-2782
DOI: 10.1021/acsbiomaterials.5c00224 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Biomaterials Science & Engineering, online erschienen am 10.04.2025. Verfasst von Dohee Ahn und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biopharmaceutical Convergence, Sungkyunkwan University, Suwon 16419, Republic of Korea. Hauptthemen laut MEDLINE: Single-Chain Antibodies, Drug Delivery Systems, Antineoplastic Agents, Oligopeptides. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Although antibody-drug conjugates offer advanced targeted anticancer therapy that overcomes the limitations of conventional chemotherapy and therapeutic antibodies, they are restricted in their capacity to carry multiple hydrophobic payloads. Protein nanocages have emerged as versatile therapeutic platforms for targeted drug delivery, offering advantages like precise molecular assembly, biocompatibility, and multivalent targeting. This study presents the development of engineered E2 nanocages functionalized with anti-HER2 single-chain variable fragments (scFv) using the SpyTag/SpyCatcher ligation system to achieve controlled scFv display valency. The results demonstrate that increasing anti-HER2 scFv valency enhances HER2 binding affinity via avidity effects, with the highest valency nanocages showing the highest binding avidity. Furthermore, cysteine residues were introduced into the E2 nanocages to enable conjugation with monomethyl auristatin E (MMAE) through maleimide chemistry, achieving efficient drug loading. The resulting MMAE-conjugated nanocages displayed potent, subnanomolar cytotoxicity in HER2-positive SKBR3 and BT-474 cell lines while sparing HER2-negative MDA-MB-231 cells at concentrations up to 1 nM. These results underscore the critical role of scFv valency in enhancing HER2 targeting and highlight the potential of E2 protein nanocages as specific, potent platforms for targeted cancer therapy. In this study, we developed an enhanced targeted drug delivery system using E2 nanocages and scFv with SpyCatcher/SpyTag ligation to regulate binding avidity and encapsulate hydrophobic drugs. The modular design and pH-sensitive dissociation of these nanocages establish a foundation for next-generation precision medicine strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biopharmaceutical Convergence, Sungkyunkwan University, Suwon 16419, Republic of Korea.
- School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea.
- AbTis Co., Ltd., Yongin 17073, Republic of Korea.
- Department of Biochemistry, College of Natural Sciences, Kangwon National University, Chuncheon 24341, Korea.
- Department of Biological Sciences, Ulsan National Institute of Science and Technology (UNIST), Ulsan 44919, South Korea.
ORCID-Profile: Dohee Ahn, Sang J Chung
Förderung
- National Research Foundation of Korea
Zitieren
APA
Ahn, D., Park, S. H., Lee, Y. G., Jeong, M. S., Gone, G. B., Cho, Y., & Chung, S. J. (2025). Enhanced Targeted Drug Delivery System to Control Avidity and Drug Encapsulation Using E2 Nanocages and SpyTag/SpyCatcher. ACS Biomaterials Science & Engineering, 11(5), 2768-2782. https://doi.org/10.1021/acsbiomaterials.5c00224
Vancouver
Ahn D, Park SH, Lee YG, Jeong MS, Gone GB, Cho Y, et al. Enhanced Targeted Drug Delivery System to Control Avidity and Drug Encapsulation Using E2 Nanocages and SpyTag/SpyCatcher. ACS Biomaterials Science & Engineering. 2025;11(5):2768-2782. doi:10.1021/acsbiomaterials.5c00224
BibTeX
@article{Ahn2025,
author = {Ahn, Dohee and Park, Sun Hee and Lee, Yeong Geun and Jeong, Myeong Seon and Gone, Geetanjali B and Cho, Younghun and Chung, Sang J},
title = {Enhanced Targeted Drug Delivery System to Control Avidity and Drug Encapsulation Using E2 Nanocages and SpyTag/SpyCatcher},
journal = {ACS Biomaterials Science & Engineering},
year = {2025},
volume = {11},
number = {5},
pages = {2768--2782},
doi = {10.1021/acsbiomaterials.5c00224}
}
EUVIMED